Health Catalyst Earnings Call Transcripts
Fiscal Year 2025
-
Revenue grew 1% in 2025 to $311.1M, with Adjusted EBITDA up 59% year-over-year. Leadership transition and strategic review are underway, with significant migration-related revenue and margin pressures expected in 2026. Q1 2026 guidance: $68–$70M revenue, $7–$8M Adjusted EBITDA.
-
Q3 2025 results exceeded guidance with $76.3M revenue and $12M adjusted EBITDA. Technology segment grew 7% YoY, while professional services declined due to contract exits. 2026 revenue is expected to dip slightly, but EBITDA should improve as cost controls and restructuring take effect.
-
Clients are adjusting to major funding cuts, leading to delayed purchases and tighter budgets. The Egnyte migration is causing near-term retention headwinds, but strong gross margins and cost savings are expected to support EBITDA growth. Capital strategy now focuses on share repurchase and debt reduction.
-
Q2 2025 revenue and adjusted EBITDA exceeded guidance, but full-year revenue outlook was cut due to major Medicaid and research funding reductions. Profitability focus is driving restructuring, cost cuts, and a shift to higher-margin technology revenue, with adjusted EBITDA guidance reaffirmed.
-
Q1 2025 revenue and adjusted EBITDA exceeded guidance, driven by strong Ignite platform adoption and robust technology segment growth. The company reiterated its full-year targets, expects improved margins in the second half, and remains confident in its cross-sell strategy and pipeline despite macroeconomic uncertainties.
-
Revenue has tripled since 2019, with a major shift to technology-driven, recurring revenue. Strategic acquisitions like Upfront and the Ignite platform transition are fueling growth, while AI innovations are driving efficiency. EBITDA is on track for 40% annual growth through 2028.
-
The conference highlighted strong momentum in technology-driven healthcare improvement, with major investments in the Ignite platform and strategic acquisitions like Upfront Healthcare. Financial guidance points to double-digit growth and expanding profitability, driven by converting app clients to platform clients and focusing on measurable ROI for healthcare organizations.
Fiscal Year 2024
-
2024 revenue grew 4% to $307M, with adjusted EBITDA up 137% to $26M. 2025 guidance projects $335M revenue, 13% tech segment growth, and $41M adjusted EBITDA. Ignite platform migration and cross-selling drive growth, with 40 new platform clients targeted for 2025.
-
Demand and pipeline have returned to pre-pandemic strength, with new client growth driven by the Ignite platform and high-performing finance and clinical apps. Margin expansion is expected as tech mix increases, offshore operations scale, and recent acquisitions enhance security and HIE offerings. Double-digit top-line and strong EBITDA growth are forecast for next year.
-
Q3 2024 revenue and adjusted EBITDA exceeded guidance, with strong technology growth and record new client additions. Full-year guidance was raised, and double-digit revenue growth with 50% adjusted EBITDA growth is targeted for 2025. Acquisition of Clearwater and robust cash position support ongoing expansion.
-
Improved market conditions and a modular Ignite platform have driven record new client wins and higher margins. The company expects double-digit revenue and 50%+ EBITDA growth in 2025, supported by a robust pipeline, tuck-in acquisitions, and strong cross-sell performance.
-
Q2 2024 revenue and adjusted EBITDA exceeded guidance, driven by strong bookings and cross-sell momentum, especially for the Ignite platform. Full-year guidance was reiterated, with double-digit growth expected in 2025, supported by new client wins, tuck-in acquisitions, and a robust financial position.